ARA 290 (Cibinetide) is a synthetic 11-amino acid peptide derived from erythropoietin (EPO). Designed to isolate EPO's tissue-protective properties without stimulating red blood cell production, it relieves chronic neuropathic pain and inflammation by activating the body's innate repair receptor. [1, 2, 3, 4]

Key Characteristics and Uses:

• Mechanism: Binds to the CD131 (common beta-receptor) to suppress pro-inflammatory cytokines and promote nerve regeneration. [1]

• Target Conditions: Preclinical and early clinical studies show promise for treating diabetic neuropathy, sarcoidosis-induced nerve pain, and general post-operative or injury-related nerve damage. [1, 2]

• TRPV1 Antagonist: Research suggests it can directly inhibit the TRPV1 channel, which helps alleviate pathophysiological pain responses. [1]

• Safety: Clinical trials have generally reported positive safety profiles with no identified cardiovascular risks associated with traditional EPO therapies, typically self-administered via daily subcutaneous injections. [1, 2, 3]

  
  

For comprehensive scientific details on its ongoing trials, you can read the ⁠PubMed Clinical Study on Sarcoidosis Patients or the ⁠National Center for Biotechnology Information Overview regarding its effects on neuropathy.

This is for informational purposes only. For medical advice or diagnosis, consult a professional.

This product for research use only.